Summary
If the major areas of prostate cancer research needing further development are discovering new targets for therapy, a better understanding of prostate cancer development, and discovery of new markers for more accurate diagnosis of prostate disease, then proteomic studies can contribute hugely to these areas. The relevance of protein rather than DNA and RNA information to such studies is that protein activity is the machinery of cell action; therefore, changes in protein profiles in cancer can be used on many levels, to detect, to understand, and finally to treat the cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sherwood ER, et al. Two-dimensional protein profiles of cultured stromal and epithelial cells from hyperplastic human prostate. J Cell Biochem 1989;40(2):201–214.
Stamatiadis D, et al. Isoelectric focusing and 2D electrophoresis of the human androgen receptor. J Steroid Biochem Mol Biol 1992;41(1):43–51.
Xia SJ, Hao GY, Tang XD. Androgen receptor isoforms in human and rat prostate. Asian J Androl 2000;2(4):307–310.
Partin AW, et al. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins. Urology 1997;50(5):800–808.
Liu X, et al. Proteomic analysis of the tumorigenic human prostate cell line M12 after microcell-mediated transfer of chromosome 19 demonstrates reduction of vimentin. Electrophoresis 2003;24(19–20):3445–3453.
Nagano K, et al. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene 2004;23(9):1693–1703.
Waghray A, et al. Identification of androgen-regulated genes in the prostate cancer cell line LNCaP by serial analysis of gene expression and proteomic analysis. Proteomics 2001;1(10):1327–1338.
Wright ME, et al. Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells. Genome Biol 2003;5(1):R4.
Gamble SC, et al. Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene 2004;23(17):2996–3004.
Alaiya AA, et al. Identification of proteins in human prostate tumor material by two-dimensional gel electrophoresis and mass spectrometry. Cell Mol Life Sci 2001;58(2):307–311.
Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 2002;50(1):54–63.
Ahram M, et al. Proteomic analysis of human prostate cancer. Mol Carcinog 2002;33(1):9–15.
Paweletz CP, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001;20(16):1981–1989.
Nelson PS, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002;99(18):11890–11895.
Eder IE, et al. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells. Mol Carcinog 2003;37(4):181–191.
Nelson PS, et al. Comprehensive analyses of prostate gene expression: convergence of expressed sequence tag databases, transcript profiling and proteomics. Electrophoresis 2000;21(9):1823–1831.
Koivisto P, et al. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998;152(1):1–9.
Visakorpi T, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9(4):401–406.
Wang LG, Liu XM, Kreis W, Budman DR. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Biochem Biophys Res Commun 1999;259(1):21–28.
Mason GG, et al. Phosphorylation of ATPase subunits of the 26S proteasome. FEBS Lett 1998;430(3):269–274.
Houry WA, et al. Identification of in vivo substrates of the chaperonin GroEL. Nature 1999;402(6758):147–154.
Ross JS, et al. Morphologic and molecular prognostic markers in prostate cancer. Adv Anat Pathol 2002;9(2):115–128.
Molloy MP. Two-dimensional electrophoresis of membrane proteins using immobilized pH gradients. Anal Biochem 2000;280(1):1–10.
Charrier JP, et al. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis. Electrophoresis 2001; 22(9):1861–1866.
Hlavaty JJ, et al. Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology 2003;61(6):1261–1265.
Lehrer S, et al. Putative protein markers in the sera of men with prostatic neoplasms. BJU Int 2003;92(3):223–225.
Yasui Y, et al. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 2003;4(3):449–463.
Petricoin EF 3rd, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94(20):1576–1578.
Adam BL, et al. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 2001;1(10):1264–1270.
Diamandis EP. Re: serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2003;95(6):489–490; author reply 490–491.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag London Limited
About this chapter
Cite this chapter
Gamble, S.C. (2005). Proteomic Approaches to Problem Solving in Prostate Cancer. In: Waxman, J. (eds) Urological Cancers. Springer, London. https://doi.org/10.1007/1-84628-015-X_10
Download citation
DOI: https://doi.org/10.1007/1-84628-015-X_10
Publisher Name: Springer, London
Print ISBN: 978-1-85233-911-1
Online ISBN: 978-1-84628-015-3
eBook Packages: MedicineMedicine (R0)